Elicio Therapeutics, Inc. Costs and Expenses in USD from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Elicio Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2020 to Q3 2025.
  • Elicio Therapeutics, Inc. Costs and Expenses for the quarter ending September 30, 2025 was $8.05M, a 22.2% decline year-over-year.
  • Elicio Therapeutics, Inc. Costs and Expenses for the twelve months ending September 30, 2025 was $42.3M, a 3.54% increase year-over-year.
  • Elicio Therapeutics, Inc. annual Costs and Expenses for 2024 was $45M, a 25.9% increase from 2023.
  • Elicio Therapeutics, Inc. annual Costs and Expenses for 2023 was $35.7M, a 50.6% increase from 2022.
  • Elicio Therapeutics, Inc. annual Costs and Expenses for 2022 was $23.7M, a 64.9% decline from 2021.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Growth (%)

Elicio Therapeutics, Inc. Quarterly Costs and Expenses (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $42.3M $8.05M -$2.3M -22.2% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $44.6M $10.1M -$833K -7.63% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $45.5M $10.7M +$495K +4.83% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 $45M $13.5M +$4.09M +43.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-31
Q3 2024 $40.9M $10.3M -$427K -3.96% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 $41.3M $10.9M +$3.15M +40.5% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $38.2M $10.2M +$2.44M +31.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 $35.7M $9.39M +$13.8M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-31
Q3 2023 $22M $10.8M +$5M +86.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $17M $7.78M +$1.55M +24.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $15.4M $7.81M -$8.33M -51.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $23.7M -$4.4M -$15.7M -139% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $39.4M $5.77M -$11.4M -66.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $50.9M $6.23M -$12.6M -66.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $63.4M $16.1M -$4.18M -20.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $67.6M $11.3M -$3M -21% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 $70.6M $17.2M +$4.81M +38.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $65.8M $18.8M +$786K +4.37% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $65M $20.3M +$6.88M +51.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $58.2M $14.3M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 $12.4M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $18M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $13.4M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17

Elicio Therapeutics, Inc. Annual Costs and Expenses (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $45M +$9.24M +25.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 $35.7M +$12M +50.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 $23.7M -$43.9M -64.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 $67.6M +$9.47M +16.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-17
2020 $58.2M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.